centerforbiosimilars1h
Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas
Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...
Healio5h
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...
centerforbiosimilars9h
Biosimilar Tocilizumab Cost-Effective for Treatment of Rheumatoid Arthritis in Spain
A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid arthritis (RA) after experiencing improved outcomes.
The Pharma Letter10h
FDA approves Lilly's Omvoh for Crohn's disease
The US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz), from US pharma major Eli Lilly, for the ...